Study wrapper · #180
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).
Editor's note
A registration-quality randomised, double-blind, placebo-controlled Phase 3 trial (SURPASS-CN-MONO) testing tirzepatide monotherapy in 206 Chinese adults with early, treatment-naive type 2 diabetes across 29 centres, funded by Eli Lilly. The blinded, placebo-controlled design and pre-specified HbA1c primary endpoint place this near the top of the evidence hierarchy; its main limits are modest size and 40-week duration, which do not speak to long-term or cardiovascular outcomes. Researchers reported HbA1c reductions of 2.04% to 2.17% across the 5, 10 and 15 mg doses versus a 0.13% placebo change (all p<0.001), and weight reductions of 6.0 to 9.7 kg versus 1.0 kg, with gastrointestinal events the most common treatment-emergent effect and no clinically significant or severe hypoglycaemia. These results are consistent with the broader SURPASS programme and add region-specific data for an East Asian population. Weight it as solid confirmatory evidence within diabetes; the industry funding and short horizon are the caveats to keep in view.
Plain-language abstract
This was a high-quality trial (randomised, double-blind, placebo-controlled) testing tirzepatide on its own in 206 Chinese adults with recently diagnosed type 2 diabetes who had not taken diabetes medicine in the previous three months. It ran at 29 hospitals in China, and participants were randomly assigned to weekly injections of 5, 10 or 15 mg of tirzepatide or a placebo, with neither patients nor staff knowing who got what. The main goal was the change in HbA1c (a three-month average blood-sugar marker) after 40 weeks. All three doses lowered HbA1c far more than placebo, by about 2.04% to 2.17% versus 0.13%. Body weight also fell more with tirzepatide, by about 6.0 to 9.7 kg versus 1.0 kg with placebo. The most common side effects in the tirzepatide groups were stomach and gut related, and there were no episodes of clinically significant low blood sugar (below 54 mg/dL) or severe low blood sugar. The authors reported that the safety profile matched earlier tirzepatide trials. The study was funded by Eli Lilly and Company.